Fighting Cancer is a Marathon Not a Sprint

  • Tamp and Tap 122 Gayoso Avenue Memphis, TN, 38103 United States

Often, when someone refers to scientific research that can be translated into the clinic, they refer to it as "bench to bedside", but with cancer research, it often goes much further than that. 

There is a big push to not only understand the disease, to treat it, and cure it, but to follow the patients in longitudinal studies, long after the cancer has gone into remission.

Come meet some scientists from St Jude who will talk to you about some of the research that is going into understanding the disease from the beginning (even before diagnosis) to the end (follow up post-remission).

Doors will be open at 6.30pm. We will have food, drinks and chatting with our new friends until 7, when the action begins!

Timeline

6:30pm

Doors will be open at 6:30pm. Enjoy a bounty of food and drinks (both with and without alcohol) offered by the Tamp and Tap while chatting with new friends.

7:00-9:00pm

Following a brief introduction to taste of science and thanks to our sponsors, we will hear from our speakers with plenty of time between for questions and refills. 

Seating is limited; only a limited number of tickets will be available for purchase at the door.

Serendipity in cancer drug discovery

Dr Anang Shelat

Associate Member, St Jude

Some of the most significant events in science were happy accidents: experiments that gave unexpected results which fundamentally changed the way we thought about the world. I will recount the discovery of the world’s first true cancer drug – a molecule that St. Jude researchers eventually adapted to treat one of the most deadly forms of pediatric cancer. I will then describe how we, using sophisticated cancer models and robotic technology, had our own serendipitous discovery.

Dr. Elizabeth Stewart

Research Associate, St Jude Faculty

  • High risk pediatric solid tumors
  • Development of patient-derived orthotopic solid tumor xenografts
  • Translational preclinical testing of novel therapeutics for pediatric solid tumors